|1.||Kazi, Aslamuzzaman: 2 articles (08/2010 - 06/2009)|
|2.||Guida, Wayne C: 2 articles (08/2010 - 06/2009)|
|3.||Sebti, Saïd M: 2 articles (08/2010 - 06/2009)|
|4.||Shen, Luqing: 1 article (01/2014)|
|5.||Luo, Peihua: 1 article (01/2014)|
|6.||Hu, Yongzhou: 1 article (01/2014)|
|7.||Wang, Jincheng: 1 article (01/2014)|
|8.||Zhang, Jiankang: 1 article (01/2014)|
|9.||Ge, Yiyu: 1 article (08/2010)|
|10.||Lawrence, Harshani R: 1 article (08/2010)|
06/15/2009 - "These results suggest that PI-083 is more selective for cancer cells and may have broader antitumor activity and therefore warrants further advanced preclinical studies."
06/15/2009 - "PI-083 inhibits CT-L activity and cell proliferation and induces apoptosis selectively in cancer cells (ovarian T80-Hras, pancreatic C7-Kras and breast MCF-7) as compared to their normal/immortalized counterparts (T80, C7 and MCF-10A, respectively). "
08/01/2010 - "Screening of the NCI Diversity Set-1 identified PI-083 (NSC-45382) a proteasome inhibitor selective for cancer over normal cells. "
06/15/2009 - "Finally, following in vivo treatment of mice, PI-083 inhibited tumor, but not hepatic liver CT-L activity, whereas Bortezomib inhibited both tumor and liver CT-L activities. "
06/15/2009 - "Furthermore, in nude mouse xenografts in vivo, PI-083, but not Bortezomib, suppressed the growth of human breast and lung tumors. "
|2.||Prostatic Neoplasms (Prostate Cancer)
|1.||Proteasome Endopeptidase Complex (Proteasome)
|1.||Heterologous Transplantation (Xenotransplantation)